
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 11, 2006

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

0-27598

(Commission File Number)

77-0210467

(IRS Employer
Identification No.)

**1212 Terra Bella Avenue
Mountain View, California 94043**

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

TABLE OF CONTENTS

[Item 2.02. Results of Operations and Financial Condition.](#)

[Item 9.01. Financial Statements and Exhibits.](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)

[EXHIBIT 99.1](#)

[Table of Contents](#)

Item 2.02. Results of Operations and Financial Condition.

On January 11, 2006, the Registrant reported its preliminary results of operations for its fourth quarter and full fiscal year 2005, which ended on December 31, 2005. A copy of the press release issued by the Registrant concerning the Registrant's results of operations for its fourth quarter and fiscal year 2005, which ended on December 31, 2005, is furnished as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated January 11, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRIDEX CORPORATION

By: /s/ LARRY TANNENBAUM

Larry Tannenbaum
Chief Financial Officer, Secretary and Senior Vice
President of Finance and Administration

Date: **January 11, 2006**

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated January 11, 2006.

FOR IMMEDIATE RELEASE

Contact: Larry Tannenbaum
Chief Financial Officer
(650) 940-4700

January 11, 2006
Mountain View, California

IRIDEX ANNOUNCES PRELIMINARY FOURTH QUARTER REVENUE

IRIDEX Corporation (NASDAQ/NMS: IRIX) today released preliminary revenue results for the fourth quarter and full-year ended December 31, 2005.

The Company is providing these preliminary results due to its scheduled presentation at the 8th Annual Needham & Company, LLC Growth Conference on Wednesday, January 11, 2006 at 4:30 p.m. Eastern Time.

Fourth quarter revenue is expected to increase more than 12% to a record level of between \$10.2 million and \$10.4 million, compared with revenue of \$9.1 million reported for the fourth quarter ended January 1, 2005. For the full-year ended December 31, 2005, revenue is expected to grow approximately 12% to \$36.8 million to \$37.0 million compared with \$32.8 million for the full-year ended January 1, 2005.

“We are pleased with our overall strong sales results which were supported by double-digit growth in both of our business segments. In 2005 we began to successfully execute our strategy of expanding our core business through new product introductions and growth of our disposable product sales. Our goal for 2006 is to again achieve double-digit revenue growth and to continue to expand our gross margin and operating income as we focus on increased operating efficiencies,” said Barry G. Caldwell, IRIDEX President and CEO.

IRIDEX plans to issue final results for the fourth quarter and full year 2005 and conduct a conference call in February.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of semiconductor-based laser systems for the ophthalmology and dermatology markets. IRIDEX products are sold in the United States through a direct sales force and internationally through a network of independent distributors into more than 100 countries. For further information, visit the Company’s website at www.iredex.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company's prospects, including growth in revenue, gross margin and operating income. Actual results could differ materially from those projected in the forward-looking statements based on, among other things, the actual order and shipment rate for the Company's ophthalmology and dermatology product lines, the rate of introduction and market acceptance of the Company's products, the financial consequences of states not reimbursing for all of the Company's AMD procedures, the impact of any continuing weakness and uncertainties related to general economic conditions or weakness in overall demand in the Company's markets, especially with regard to the Company's dermatology products which are typically used for elective procedures that can be deferred, and the Company's ability to continue to reduce its costs and improve its operating efficiencies. Risks and uncertainties to which the Company are subject may include, but may not necessarily be limited to, the amount of orders that the Company receives and ships, dependence on international sales and the Company's network of independent distributors, the risks associated with bringing new products to market, the results of clinical trials and competition in our markets. Please see a detailed description of these risks contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended January 1, 2005 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.